Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor
go back to main search page
Accession:CHEBI:76733 term browser browse the term
Definition:An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on NADH or NADPH (EC 1.6.*.*).
Synonyms:related_synonym: inhibitor of oxidoreductase acting on NADH or NADPH;   inhibitor of oxidoreductase acting on NADH or NADPH (EC 1.6.*);   inhibitors of oxidoreductase acting on NADH or NADPH;   inhibitors of oxidoreductase acting on NADH or NADPH (EC 1.6.*);   oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitors;   oxidoreductase acting on NADH or NADPH inhibitor;   oxidoreductase acting on NADH or NADPH inhibitors



show annotations for term's descendants           Sort by:
apocynin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CCL2 chemokine (C-C motif) ligand 2 multiple interactions
decreases expression
EXP acetovanillone inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA]
acetovanillone results in decreased expression of CCL2 mRNA
CTD PMID:23380242 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 multiple interactions EXP acetovanillone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] CTD PMID:24512358 NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions EXP acetovanillone inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] CTD PMID:23380242 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
JBrowse link
curcumin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACO2 aconitase 2 multiple interactions EXP Curcumin inhibits the reaction [maleic acid results in decreased activity of ACO2 protein] CTD PMID:25119790 NCBI chr 5:7,014,383...7,071,023
Ensembl chr 5:7,008,719...7,071,025
JBrowse link
deguelin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP deguelin results in increased expression of and results in increased phosphorylation of AKT1 protein CTD PMID:37353039
G PDK1 pyruvate dehydrogenase kinase 1 multiple interactions EXP deguelin results in increased expression of and results in increased phosphorylation of PDK1 protein CTD PMID:37353039 NCBI chr15:78,608,394...78,650,958
Ensembl chr15:78,608,432...78,652,962
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP deguelin results in increased expression of and results in increased phosphorylation of PIK3R1 protein CTD PMID:37353039 NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,511,521...46,523,609
JBrowse link
G PTEN phosphatase and tensin homolog multiple interactions EXP deguelin results in increased expression of and results in increased phosphorylation of PTEN protein CTD PMID:37353039 NCBI chr14:99,929,590...100,021,619 JBrowse link
dicoumarol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP Dicumarol inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]] CTD PMID:20732396 NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
JBrowse link
rotenone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NOS3 nitric oxide synthase 3 increases expression EXP Rotenone results in increased expression of NOS3 mRNA CTD PMID:11382920 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
JBrowse link
warfarin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BMP2 bone morphogenetic protein 2 multiple interactions
increases expression
EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein; leptomycin B inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]]; LRP6 protein affects the reaction [Warfarin results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA] CTD PMID:29358327 PMID:34520801 NCBI chr17:15,750,487...15,762,982
Ensembl chr17:15,749,835...15,761,195
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein CTD PMID:29358327 NCBI chr 7:32,354,776...32,363,771
Ensembl chr 7:32,359,455...32,363,761
JBrowse link
G EP300 E1A binding protein p300 multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein CTD PMID:29358327 NCBI chr 5:7,311,165...7,394,515
Ensembl chr 5:7,311,171...7,393,760
JBrowse link
G LRP6 LDL receptor related protein 6 multiple interactions
increases expression
EXP LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [Warfarin results in increased expression of BMP2 mRNA]; LRP6 protein affects the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SOX5 protein promotes the reaction [Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]]; SOX5 protein promotes the reaction [Warfarin results in increased expression of LRP6 protein]; Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]
Warfarin results in increased expression of LRP6 mRNA; Warfarin results in increased expression of LRP6 protein
CTD PMID:34520801 NCBI chr 5:60,149,041...60,318,719
Ensembl chr 5:60,149,028...60,314,662
JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions
increases expression
EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein; Ammonium Chloride inhibits the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SOX5 protein inhibits the reaction [Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 protein]; Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]
Warfarin results in increased expression of RUNX2 mRNA; Warfarin results in increased expression of RUNX2 protein
CTD PMID:29358327 PMID:34520801 NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687
JBrowse link
G SNAI2 snail family transcriptional repressor 2 multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]; Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter] CTD PMID:29358327 NCBI chr 4:79,264,880...79,268,475
Ensembl chr 4:79,264,880...79,268,475
JBrowse link
G SOX5 SRY-box transcription factor 5 decreases expression
multiple interactions
EXP Warfarin results in decreased expression of SOX5 mRNA
Ammonium Chloride inhibits the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]]; LRP6 protein affects the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]; SOX5 protein affects the reaction [Warfarin results in decreased expression of SOX9 mRNA]; SOX5 protein inhibits the reaction [Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]]; SOX5 protein inhibits the reaction [Warfarin results in decreased expression of and affects the localization of SOX9 protein]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of BMP2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]; SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 protein]; SOX5 protein promotes the reaction [Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]]; SOX5 protein promotes the reaction [Warfarin results in increased expression of LRP6 protein]; Warfarin promotes the reaction [SOX5 protein binds to SOX9 promoter]; Warfarin results in decreased expression of and affects the localization of SOX5 protein
CTD PMID:34520801 NCBI chr 5:49,159,950...50,166,463
Ensembl chr 5:49,504,551...50,161,558
JBrowse link
G SOX9 SRY-box transcription factor 9 multiple interactions
decreases expression
EXP SOX5 protein affects the reaction [Warfarin results in decreased expression of SOX9 mRNA]; SOX5 protein inhibits the reaction [Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]]; SOX5 protein inhibits the reaction [Warfarin results in decreased expression of and affects the localization of SOX9 protein]; SOX5 protein promotes the reaction [Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]]; Warfarin promotes the reaction [SOX5 protein binds to SOX9 promoter]; Warfarin promotes the reaction [SOX9 protein binds to LRP6 promoter]; Warfarin promotes the reaction [SOX9 protein binds to RUNX2 promoter]; Warfarin results in decreased expression of and affects the localization of SOX9 protein CTD PMID:34520801 NCBI chr12:8,642,154...8,647,315
Ensembl chr12:8,642,158...8,647,315
JBrowse link
G TP53 tumor protein p53 increases response to substance
increases expression
multiple interactions
EXP TP53 protein results in increased susceptibility to Warfarin
Warfarin results in increased expression of TP53 mRNA
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]; Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter]; Warfarin results in increased expression of and results in decreased acetylation of TP53 protein
CTD PMID:29358327 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 5162
    role 5129
      biological role 5129
        biochemical role 5041
          enzyme inhibitor 522
            EC 1.* (oxidoreductase) inhibitor 114
              EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor 19
                EC 1.6.3.* (oxidoreductase acting on NADH or NADPH with oxygen as acceptor) inhibitor + 3
                EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor + 16
                circumdatin H 0
paths to the root